Mallinckrodt PLC operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Mallinckrodt PLC with three other
companies in this sector in the United States:
Alexion Pharmaceuticals, Inc.
sales of $3.08 billion
of which 100%
was Therapeutic Products),
Endo International PLC
of which 64%
was Generics), and
Dr.Reddy's Laboratories Ltd
of which 83%
was Global Generics).
Mallinckrodt PLC reported sales of $3.38 billion
December of 2016.
a very small
increase of 1.0%
versus 2015, when the company's sales were $3.35 billion.
Sales at Mallinckrodt PLC have increased during each of the previous five years
(and since 2011, sales have increased a total of 67%).
Sales of Specialty Brands saw an increase
that was more than double the company's growth rate: sales were up
41.8% in 2016, from
$1.62 billion to $2.30 billion.
Mallinckrodt PLC also saw significant increases in sales in
Corporate/unallocated (up 12.9% to $55.00 million)
Not all segments of Mallinckrodt PLC experienced an increase in sales in 2016:
sales of Specialty Generics fell 18.1% to $1.03 billion.